PER-012-13未知未知
A DOUBLE-BLIND, PLACEBO-CONTROLLED,RANDOMIZED, MULTICENTER PHASE III STUDYEVALUATING THE EFFICACY AND SAFETY OFPERTUZUMAB IN COMBINATION WITHTRASTUZUMAB AND CHEMOTHERAPY IN PATIENTSWITH HER2-POSITIVE METASTATICGASTROESOPHAGEAL JUNCTION AND GASTRICCANCER.
适应症
试验速览
- 阶段
- 未知
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 90（—）
入选标准
- •1. Gastric adenocarcinoma or histologically confirmed metastatic GEJ (by performing the enrollment center)
- •2. HER2-positive tumors defined as IHC 3 + or IHC 2 +, the latter in combination with ISH +, as assessed by a central laboratory designated by the sponsor in a primary or metastatic tumor
- •3. Measurable or evaluable disease not measurable, as assessed by the investigator, according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, see Appendix 3
- •4. Performance status (PS) 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG)
- •5. Life expectancy ≥ 3 months
- •6. Age ≥ 18 years
- •7. Ability to meet the requirements of the protocol, as assessed by the investigator
- •8. Signing of Informed Consent.
排除标准
- •1. Prior systemic cytotoxic chemotherapy for advanced disease (metastatic).
- •2. History of exposure to cumulative doses of anthracyclines following:
- •a) Epirubicin> 720 mg/m2, b) or doxorubicin liposomal doxorubicin> 360 mg/m2, c) Mitoxantrone> 120 mg/m2 and idarubicin> 90 mg/m2, d) Other (for example, liposomal doxorubicin or other anthracycline greater the equivalent of 360 mg/m2 of doxorubicin) e) If you have used more of an anthracycline, then the cumulative dose should not exceed the equivalent of 360 mg/m2 of doxorubicin.
- •3. Evidence of documented disease progression in the span of six months after completion of neoadjuvant or adjuvant cytotoxic chemotherapy earlier, or both, or radiotherapy for adenocarcinoma of the gastric or GEJ.
- •4. Pretreatment with any HER2-directed therapy, at any time and for any duration.
- •5. Prior exposure to any investigational treatment within the span of 30 days prior to the first dose of study treatment.
- •6. Radiation in the span of 30 days prior to the first dose of study treatment (within 2 weeks if it is administered as a palliative for bone metastases peripheral, if the patient has recovered from all toxicities).
- •7. History or evidence of brain metastases.
- •8. Active GI bleeding clinically significant (≥ Grade 2 according to the Common Terminology Criteria for Adverse Events [CTCAE] v4.03 of the National Cancer Institute [NCI]).
- •9. Residual toxicity caused by previous therapy (eg hematologic toxicity, neurological or cardiovascular be ≥ Grade 2). Alopecia is permitted.
- •10. Another malignancy (besides GC) is presented in the span of 5 years prior to enrollment, except for carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin that has been previously treated with curative intent.
研究者
相似试验
招募中
不适用
A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL ASSESSING THE IMPACT OF LIPOPROTEIN (A) LOWERING WITH TQJ230 ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE-I516 Cardiovascular disease, unspecifiedCardiovascular disease, unspecifiedI516PER-085-20ovartis Pharma AG.,
进行中（未招募）
不适用
This is a study of two investigational drugs called onartuzumab and bevacizumab that are being tested alone or in combination with each other for the treatment of a specific type of brain tumor called glioblastoma.EUCTR2011-005912-27-ESF. Hoffmann-La Roche Ltd.180
进行中（未招募）
不适用
This is a study of two investigational drugs called onartuzumab and bevacizumab that are being tested alone or in combination with each other for the treatment of a specific type of brain tumor called glioblastoma.EUCTR2011-005912-27-ITF. HOFFMANN - LA ROCHE LTD.180
进行中（未招募）
不适用
This is a study of two investigational drugs called onartuzumab and bevacizumab that are being tested alone or in combination with each other for the treatment of a specific type of brain tumor called glioblastoma.EUCTR2011-005912-27-DEF. Hoffmann-La Roche Ltd.125
已完成
3 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TOCILIZUMAB IN PATIENTS WITH SEVERE COVID-19 PNEUMONIAPneumoniaNL-OMON50069F. Hoffmann-La Roche Ltd20